Six-Month Safety and Effectiveness of Teduglutide in Patients with Short Bowel Syndrome in Japan: Interim Analysis of Post-marketing Surveillance
Authors:
Open Access
- 1 December 2025
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (1) , 425-441
Abstract
Introduction Patients with intestinal failure caused by short bowel syndrome (SBS) are dependent on parenteral support (PS) for nutrition. Teduglutide, an analogue of glucagon-like peptide 2, has been shown to decrease reliance on PS with an acceptable safety profile in multiregional phase 3 clinical trials, but currently there are no reports examining treatment outcomes with teduglutide in the real-world population in Japan. This interim analysis of a 36-month post-marketing surveillance (PMS) reports the safety and effectiveness of teduglutide in adults and pediatric patients with SBS in Japan. Methods This 6-month analysis was conducted as part of a prospective, all-case, 36-month PMS of teduglutide (Takeda Pharmaceutical Company Limited) conducted in patients with SBS across 102 sites in Japan. All patients who started teduglutide treatment from August 2021 to August 2022 were enrolled. Safety and effectiveness were evaluated after 6 months of teduglutide treatment and compared with baseline. Results A total of 123 patients aged 2–83 years were included in the safety analysis, including 27 children (aged < 15 years). A total of 51 patients (44 adults, 7 children) reported 117 adverse drug reactions (ADRs). In adults, the most common ADRs were abdominal distension (10.42%), abdominal pain (10.42%), stoma complication (8.33%), and nausea (7.29%). In children, the most common ADR was abdominal pain (11.11%). In the effectiveness analysis, 11.9% (12/101) of patients were able to wean off PS and 42.4% (39/92) were able to achieve at least 20% reduction in their PS volume. The overall mean (standard deviation) change from baseline in the z-score of body weight in children (n = 20) was 0.185 (0.2964). Conclusion In this interim analysis of a 36-month PMS, teduglutide demonstrated an acceptable safety profile and promising effectiveness in patients with SBS. Trial Registration ClinicalTrials.gov identifier, NCT05023382.Keywords
Funding Information
- Takeda Pharmaceutical Company
This publication has 40 references indexed in Scilit:
- Adult patients with short bowel syndrome treated with teduglutide: A descriptive cohort studyJournal of Parenteral and Enteral Nutrition, 2023
- Efficacy, safety, and pharmacokinetics of teduglutide in adult Japanese patients with short bowel syndrome and intestinal failure: two phase III studies with an extensionSurgery Today, 2022
- Impact of intestinal failure and parenteral support on adult patients with short‐bowel syndrome: A multinational, noninterventional, cross‐sectional surveyJournal of Parenteral and Enteral Nutrition, 2022
- Etiologies and treatments of chronic intestinal failure-short bowel syndrome (SBS) in Japanese adults: a real-world observational studySurgery Today, 2022
- Impact of infusion frequency on quality of life in patients receiving home parenteral nutritionJournal of Parenteral and Enteral Nutrition, 2021
- Teduglutide in short bowel syndrome patients: A way back to normal life?Journal of Parenteral and Enteral Nutrition, 2021
- Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24‐Week, Phase III StudyJournal of Parenteral and Enteral Nutrition, 2019
- Intestinal Failure-Associated Liver DiseaseClinics in Liver Disease, 2019
- Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal FailureJournal of Parenteral and Enteral Nutrition, 2019
- Current use and clinical outcome of home parenteral and enteral nutrition therapies in the United StatesGastroenterology, 1995